E5564, a synthetic lipid A analogue, is a selective, highly active antagonist of endotoxin-mediated activation of immune cells. Preclinical research has indicated that E5564 can block endotoxinmediated induction of cytokines and endotoxin or Gram-negative bacterial-induced death in animal models. Recent phase I clinical trials have focused on the ability of E5564 to block responsiveness to endotoxin. This was done in two ways: in vivo challenge of human volunteers with 4 ng/kg endotoxin, and by use of an ex vivo assay which utilizes blood drawn from volunteers administered E5564 and challenged with endotoxin at concentrations that ranged from 50 pg/ml to 10 ng/ml. In vivo, 100 mg of E5564 completely blocked signs, symptoms and cytokines induced by concomitantly-administered endotoxin. In contrast, subjects receiving a 50 mg dose of E5564 demonstrated a graded response; cytokines were inhibited 95%, but many signs and symptoms of endotoxemia were still evident. E5564 demonstrated a long pharmacokinetic half-life (> 30 h); however, ex vivo analysis indicated that while single doses of 350 mg induced a nearly complete block of the effects of 1 ng/ml endotoxin immediately upon E5564 administration, antagonistic activity declined rapidly (t 1/2 < 1 h). Similar results were obtained in vivo using a delayed endotoxin challenge. These results have driven us to examine antagonistic activity of E5564 in vivo and ex vivo after administration by continuous infusion or twice-daily dosing. Results from these multiple-dose studies indicate that under these conditions of administration, plasma levels of E5564 can be predictive of long-term pharmacodynamic activity.
INTRODUCTION
Endotoxin (lipopolysaccharide, LPS) is a uniquelystructured, major component of the outer membrane of Gram-negative bacteria which can alert the innate immune system to the presence of an infectious organism. Besides being a marker of the presence of bacteria in normally sterile tissues, LPS from Gram-negative enteric commensal bacteria is normally present at high levels in the intestine. Whether derived from the infectious organism or translocated across the intestinal wall, LPS has been implicated as an etiological factor in the development of sepsis and septic shock. 1 In addition to sepsis, a variety of other pathological responses such as the systemic inflammatory response from cardiovascular 2 or vascular surgery 3 have been attributed to endotoxin translocated from the intestine. The lipid A portion of LPS is responsible for LPS-mediated syndromes. E5531 is a synthetic lipodisaccharide designed to antagonize the toxic effects of lipid A and has its structure derived from the non-toxic bacterium Rhodobacter capsulatus. 4 E5564 is a second-generation synthetic lipid A analogue that bears similarities to the lipid A from the non-toxic bacterium R. sphaeroides. Like E5531, it has been shown to block the action of LPS at its cell-surface receptor (TLR4) and thereby blocks in vitro and in vivo induction of cellular mediators (e.g. TNF-, IL-6, etc.). 5 Timely administration of E5564 into septic patients or pretreatment of patients at risk of LPS exposure may prove to be therapeutically beneficial.
MATERIALS AND METHODS
E5564 or corresponding placebo was reconstituted with sterile water, diluted in 5% dextrose in water (USP) and infused intravenously.
In vitro, in vivo and ex vivo assays using human or animal whole blood were performed as described. [4] [5] [6] [7] Safety and tolerability to E5564 during and after infusion into normal volunteers were assessed by monitoring vital signs, clinical laboratory values, ECGs, and general health and well-being of subjects prior to, during, and after test drug administration. The frequency, type, severity, and relationship to study drug of treatmentemergent signs and symptoms (TESS) were compared across treatments.
The human endotoxin challenge model was studied as described. 8 All potential volunteers signed a written informed consent before study-related procedures were undertaken.
Descriptive statistics were compiled for vital signs measurements and ECG measurements at baseline and post-dose, along with the change between these timepoints. For serum chemistry and hematology tests, the study pre-dose (baseline) and post-dose measurements, along with the change between these time-points were summarized. Shift tables for serum chemistry, hematology, and urinalysis laboratory tests were constructed. Out-of-range clinical laboratory results and their associ-ated re-check values were noted. These data were used to identify clinically significant treatment-emergent abnormal values.
RESULTS AND DISCUSSION
The structure of E5564 has some similarity to that of our first generation antagonist, E5531 4,5 however, as shown in Figure 1 , E5564 lacks the secondary side chain at position 3 , and at the 2 position has an extended side chain possessing a cis-double bond ( 11 ). These alterations have improved several attributes of these antagonists.
Improved synthesis, purification, stability, and formulation
As shown in Figure 1 , replacement of the double side chain at the 3 position of E5531 with cis-vaccenic acid simplifies the synthesis of E5564. In addition, reducing the number of hydrophobic side chains enhances solubility. This is likely a factor in our observation that E5564 is easier to purify and formulate into a readily dispersible lyophilizate. Finally, stability data indicate that, like E5531, E5564 is suitably stable for pharmaceutical applications. 
Safety
Intermittent infusion toxicokinetic studies in dogs indicated that exposure to E5564 at steady-state plasma levels 20-40 mg/ml for 14 days was safe.
Activity and duration of activity
E5564 is approximately 7-fold more potent as an antagonist than E5531 in vitro in human blood. Increased activity is also seen in vivo in animals and in the human endotoxemia model (see below). In vivo, E5564 administered intravenously appears to be confined to the vascular space and demonstrates a long plasma half-life and low plasma clearance, similar to that of E5531. 8 However, antagonistic activity of both E5531 and E5564 decreases while remaining in the circulation, even though they appear to be chemically unmodified. This is likely due to the binding of these molecules to lipoproteins, especially HDL. As described below, we have established that quantitative inactivation of E5564 by lipoproteins can be circumvented by manipulation of the method of administration.
Preclinical studies
When tested in a mouse macrophage cell line, the presence of serum was not necessary for E5564 to be an effective LPS antagonist, suggesting that E5564 did not inhibit LPS activity through soluble transfer proteins such as LBP and CD14. We have previously shown that E5531 works as an LPS antagonist by interacting at TLR4. 9 Similar assays using cells transfected with TLR4 and MD2 indicated that E5564 similarly acts in these cells to block LPS-mediated activation of NF-B (manuscript in preparation). We have used in vitro assays to measure inhibition of endotoxin or bacterial-mediated stimulation (e.g. release of TNF-and other cytokines) of primary cultures of human myeloid cells and mouse tissue culture macrophage cell lines, as well as human and animal whole blood. In all these systems, indices of LPS-mediated cellular stimulation, such as release of TNF-, IL-6, IL-1 , IL-10, and NO, and activation of NF-B were inhibited by E5564, generally with IC 50 values in the low nanomolar range. In whole human blood, TNF-release induced by 10 ng/ml LPS was completely inhibited by approximately 10 nM (14 ng/ml) E5564. E5564 also blocked the ability of Gram-negative bacteria (Escherichia coli or Enterobacter aerogenes) to stimulate human cytokine production in whole blood (Fig.  2) . But, perhaps not surprisingly, up to 1 mM E5564 had no measurable suppressive effect on cytokine response to Gram-positive bacteria in the whole blood assay.
Inhibition of stimulation by whole bacteria and LPS by low concentrations of E5564, coupled with the observation that E5564 inhibition is specific for TLR4-mediated stimulation, argues that LPS activation of cells via TLR4 is the primary means of induction of inflammatory response to Gram-negative bacteria. Further support for this observation comes from the finding that the 'downstream' program of gene response of human macrophages stimulated with whole bacteria is highly congruent to that observed with LPS alone. 10 In vivo results E5564 was devoid of LPS-like agonistic activity in BCGprimed mice. 5 In this model system, E5564 blocked induction of LPS-induced cytokines or LPS-induced mortality. In a more complex system of bacterial infection designed to cause 90% mortality, E5564 demonstrated only weak reduction in mortality when tested alone (16% relative reduction), as did antimicrobial therapy (28% relative reduction with latamoxef) alone. However, when both antimicrobial treatment and E5564 were co-administered, synergistic protection (87% relative reduction; P < 0.05) was observed. Previous studies have demonstrated that high levels of plasma endotoxin are found when latamoxef is administered to septic animals, and that mortality in such animals can be blocked by E5531. 4 Again, the observation that LPS is the likely agent of bacterial-induced lethality solution to 400 ml of heparinized human blood followed by 100 ng of whole bacteria added as 50 ml of a 10x suspension of the lyophilized bacteria in distilled water. After 3 h incubation at 37°C, plasma was separated and TNF-was measured by ELISA assay. Results shown are the mean of those obtained in three assays each analyzed for TNF-. The IC 50 for E5564 in these assays is 1.2 ± 0.5 nM against Ent. aerogenes and 0.65 ± 0.32 nM against E. coli.
(E5531-attenuated mortality) has also been elucidated in studies described by Morrison and co-workers. 11 These results support the conclusion that E5564 is not an antimicrobial treatment, but can supplement the lifesaving effects of antimicrobial therapy by blocking deleterious cytokine responses induced by dead and dying bacteria.
Clinical research
Six phase I clinical studies in normal male and female volunteers (one study in females) have assessed the safety, pharmacokinetics and pharmacodynamics of E5564 administered as a single short infusion (0.5-3.5 mg over 30 min), continuous infusion (72-h infusion of 0.5-3.5 mg/h) or twice-daily dosing adjusted to maintain plasma levels of 1, 2.6 or 10 mg/ml.
Safety of E5564
Six studies involving administration of E5564 to over 120 normal volunteers have indicated that besides phlebitis, no clinically significant or dose-related changes in vital signs, physical examination or ECG findings were observed. Phlebitis at the site of E5564 administration occurred in a time-and concentration-dependent manner. In general, phlebitis was common in subjects receiving E5564 at concentrations of 0.5 mg/ml for 8 h or more, or after multiple doses. This phlebitis resolved during the follow-up period.
Pharmacokinetics
E5564 pharmacokinetic (PK) data were collected during all six phase I studies. Briefly, most PK parameters are similar or correlated with dose, whether administered as a single short infusion, continuous infusion or twicedaily doses. When administered intravenously, E5564 had a low volume of distribution (41-64 ml/kg), apparently remaining confined to the vascular space, and demonstrated linear dose-dependence for maximum observed plasma concentration (C max ). E5564 is cleared from plasma at a slow rate (CL = 0.7-1.4 ml/kg/h) and has a long plasma half-life (t 1/2 = 41-62 h). Total exposure (area under the plasma concentration time curve, AUC) is dose-dependent, but increases greater than dose-proportionately at high dose. Once adjusted to body weight, no significant differences in PK parameters were found between men and women.
E5564 binds principally to lipoproteins in the blood (Table 1) . During 72 h infusion, E5564 was predominantly associated with HDL (> 60%), and approximately 10% was associated with plasma proteins (lipoproteindeficient plasma, LPDP) fraction.
Previously, E5531 was shown to associate with plasma lipoproteins causing low concentrations to be quantitatively inactivated in a dose-and time-dependent fashion. 7, 12 More recently, similar results have been observed for E5564 in vitro; however, while low concentrations (1-100 nM) of E5564 can quantitatively lose activity, higher concentrations appeared to retain activity in whole blood. This observation provides a likely explanation of results obtained from the ex vivo and in vivo studies described below.
Pharmacodynamics
Pharmacodynamic measurements have been performed ex vivo, by testing LPS response in blood drawn from E5564-treated volunteers, and in vivo by administering endotoxin to normal volunteers previously given E5564.
The ex vivo assay enables us to do multiple LPS 'challenges' to blood from each volunteer, thereby measuring time-related pharmacodynamics in each individual. In addition, previous in vitro results indicated that E5564 was a competitive inhibitor of LPS, making it important to determine E5564 dose response as a function of different concentrations of agonist. For these reasons, concentrations of 1 and 10 ng/ml LPS were employed in these studies. The selection of the 1 ng/ml endotoxin challenge level was based on a report that this level was frequently measured in septic patients with Gram-negative, Gram-positive or fungal infections. 1 We propose that ex vivo protection against 10 ng/ml of LPS would likely provide an excess Values are the mean of 5 time-points taken during the 72-h infusion. In each case, recovery of E5564 was 87% of the total measured in the starting plasma sample. LPDP, lipoprotein-deficient plasma.
or 'margin' of antagonistic activity sufficient to block endotoxin response in even severely septic patients. Ex vivo analysis of the antagonistic activity of 0.5, 1.0, 2.0, and 3.5 mg E5564 administered over 30 min indicated that immediately after ending the infusion, all doses completely or nearly completely blocked cytokine activation by 1 ng/ml LPS ( Table 2) . Less inhibition was observed after challenge with 10 ng/ml of LPS, demonstrating that response was dependent on both LPS and E5564 concentrations. LPS antagonistic activity of E5564 was dramatically reduced when endotoxin challenge was performed with blood samples collected at intervals up to 7.5 h after ending the 30-min infusion ( Table 2 ). This is likely due to the observation that E5564 binds rapidly to lipoproteins which have been shown to inactivate low doses of antagonist (unpublished data).
In vivo pharmacodynamics
Based on our observation that the first generation antagonist (E5531) could completely block signs and symptoms of endotoxemia as well as reduce cytokines induced by 4 ng/kg LPS by > 99%, 8 we defined the minimum effective dose (MED) of E5564 as the lowest dose that completely blocked all signs and symptoms of endotoxemia in healthy volunteers given a similar dose of endotoxin. To this end, endotoxin (4 ng/kg) was administered at the midpoint of a 30 min infusion of 250, 100, or 50 mg of E5564. The 250 and 100 mg doses of E5564 completely blocked signs, symptoms and cytokines induced by concomitantly-administered LPS. As shown in Table 3 , IL-6 and TNF-release in subjects given 100 mg of E5564 were reduced by > 99%, and release of C-reactive protein (CRP) was inhibited by > 91%. This reduction in cytokines was accompanied by reduction in the incidence of chills and headaches, as well as absence of tachycardia and changes in circulating white blood cells. Fever, defined as an oral temperature > 100°F, was absent. Similar results were obtained using infusions of 250 mg E5564.
In contrast, subjects administered a 50 mg dose experienced a less dramatic reduction in endotoxin response. Cytokine release was inhibited > 95% (Table 3) , but many signs and symptoms of endotoxemia including low grade fever (mean peak temperature increase was 1.9°F versus 4.1°F peak increases in temperature in placebo-treated subjects) were evident.
Based on these results, it was concluded that the MED of E5564 was 100 mg. This potency appears to be slightly greater than that of our first-generation antagonist. 8 As predicted by our ex vivo assays, low doses of E5564 did not maintain activity for an extended period of time. When 4-fold higher doses of E5564 (400 mg) were administered to subjects followed by endotoxin challenge 6 h later, cytokine response was blunted and Antagonism of response to LPS by E5564, a synthetic lipid A analogue 487 Inhibition of mean maximal increase in each cytokine compared to response of subjects receiving placebo and endotoxin. Subjects were infused intravenously with the indicated amount of E5564 over 30 min and endotoxin (4 ng/kg) was injected into the contralateral antecubital vein at the mid-point of E5564 infusion. Baseline plasma samples were obtained 1 h before beginning E5564 infusion and every 30 min after beginning infusion until 3 h, and at hours 4, 6, 12, 16, and 24. Mean maximal increases for cytokines in placebo-infused subjects were determined to be at 2 h for TNF-and at 4 h for IL-6. Mean maximal increases for TNF-and IL-6 in the E5564-infused subject were at 2 h (TNF-) and at 3 h (IL-6), but the low cytokine levels in the treated volunteers yielded extremely flat response curves over time. C-reactive protein was measured at 24 h.
the signs, symptoms and other clinical indicators of endotoxemia were evident, but decreased. These safety and pharmacokinetic/pharmacodynamic results encouraged us to test if E5564 could be administered at doses high enough to completely inhibit LPS response for an extended period. Thus, an escalating dose study of up to 252 mg administered continuously over 72 h, achieving plasma concentrations greater than 40 mg/ml and an ascending-dose twice-daily dosing study was performed in normal volunteers.
Results from this study indicated that effective plasma levels of E5564 could be safety attained that would provide a complete block of the signs, symptoms, and cytokine responses to LPS for 12 h or more after dosing.
CONCLUSIONS
Results from our preclinical and clinical studies support the following arguments: (i) E5564 is a potent antagonist of LPS both in vitro and in vivo and lacks agonistic activity in human and animal model systems; (ii) antagonism is dependent on the concentrations of E5564 and LPS; (iii) in vivo, onset of inhibitory action is rapid, and not likely the product of a secondary event such as induction of glucocorticoids or tolerance to LPS; and (iv) while the antagonistic activity of low doses of E5564 decreases over time, sufficiently high doses of E5564 could be safely infused to retain activity with a twice-daily dosing regimen. These results lead us to believe that E5564 can be safely administered in the clinic. The safety and effectiveness of E5564 as a therapeutic agent for treatment of diseases for which endotoxin is believed to play a role is now being evaluated in phase II studies.
